Drug Recommendation

Cabotegravir has not yet been reviewed for inclusion in the DHHS list of recommended medications for HIV treatment or prevention.

General Info

Cabotegravir is an experimental long-acting injectable HIV medication. It contains one integrase inhibitor. It is currently in Phase III clinical trials for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Dosage

Dosing Info:

This is a long-acting injectable HIV medication administered every eight weeks.